͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Join us for the second webinar in our series exploring children’s and young people’s cancers to look at the role of clinical trials in increasing our understanding of cancer biology and treatments for paediatric cancers.
We will feature researchers working at the interface between clinical and discovery research discussing how to maximise learnings from clinical trials to develop future studies and more effective, less toxic treatments.
Graham Cadwallader, Head of Clinical Research, will chair. He will touch on our new clinical research funding scheme and how it is designed to support studies bridging the gap between discovery and clinical research.
Join us online on 12 February, 3 – 4:30pm (GMT).
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | Applications accepted year round |
|
|---|
| | | | | | Applications accepted year round |
|
|---|
| | | | | | Applications accepted year round |
|
|---|
|
| | |
|
|
What’s on the horizon for the life sciences industry? |
| As 2024 draws to a close, our colleagues at our innovation arm, Cancer Research Horizons, have shared their thoughts on what 2025 may bring to the life sciences industry.
From new policies brought in by the many recent changes of government across the world, through the ongoing funding challenges in academia, to the latest trends in drug discovery and investment, our experts take you through next year's opportunities and threats that may affect how we can deliver patient benefit. |
| | |
|
|
|
| | | | | What does an ideal working environment look like to you? Does it have controlled lighting and temperature? Adjustable desks? Silence? Flexibility?
The EDI Caucus wants your input to help with the future design of better and more enabling workspaces for the research and innovation ecosystem. Share your experiences of both good workplace design, and examples of where it could have been improved.
There will be two online workshops for general admission on 22 and 23 January, 2 - 3pm. Another online workshop will be held for deaf BSL-users on 21 January, 3 – 4pm. You may also be able to receive remuneration for taking part. | | |
| | | | | | | The Public Engagement in Data Research Initiative (PEDRI) is a partnership between UK organisations to shape better data research by promoting transparency, diverse voices and good public engagement practices.
You can find guidance like the Good Practice Standards, co-created with the public, and events and news to help you work well with the public on PEDRI’s new website. | | |
|
|---|
|
|
|
|
Optimising data and samples reuse survey |
| Help us explore the reuse opportunities for data and samples in clinical and biological cancer research.
Our data and samples reuse special interest group is running a survey to help us understand how you’re currently using data and samples in your research and what challenges you’re encountering.
We’ll use this information to build on the support we provideto researchers so that they can maximise the use of data for patient benefit. |
| | |
|
|
|
| | | | | In 2018 a group of postgrads from the University of Cambridge founded a company to develop low-cost products to streamline urgent care pathways and enhance patient safety across all socio-economic groups.
This month 52North has raised $6m to develop devices that help patients manage their cancer treatment.
Its flagship product, Neutrocheck, aims to enable patients to monitor their risk of neutropenia or neutropenic sepsis, a potentially life-threatening complication of chemotherapy.
The funding round is the first instance of an investment being co-led by hospital venture funds on both sides of Atlantic. Several other non-profit investors, including Cancer Research Horizons and Macmillan Cancer Support, made significant contributions. | | |
| | | | | | | How can a particle accelerator help find new cancer treatments? By producing light 10 billion times brighter than the sun. This is why Cancer Research Horizons is partnering with the UK’s national synchrotron, Diamond Light Source.
Diamond Light Source accelerates electrons to near light speed, producing intense beams of X-rays, infrared and ultraviolet light. This will allow Cancer Research Horizons’ drug discovery scientists to use these beamlines for fragment-based screening, a technique to identify chemical entities that can be rapidly developed into drug candidates.
“By combining our cutting-edge synchrotron technology with the expertise of Cancer Research Horizons,” said Elizabeth Shotton, Diamond Light Source’s Head of Industrial Liaison, “we aim to support the development of new cancer treatments.” | | |
|
|---|
|
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
